This article is more than 5 years old. Information may no longer be current.
VIVA 17 to highlight integrated approaches to treat vascular disease
Click Here to Manage Email Alerts
Experts from multiple disciplines will converge to learn about the best ways to treat vascular disease in a variety of forms at VIVA 17.
The conference, to be held Sept. 11 to 14 at the Wynn in Las Vegas, “stands for an integrated approach,” Gary M. Ansel, MD, FACC, system medical chief for vascular at OhioHealth in Columbus and a Cardiology Today’s Intervention Editorial Board Member, said in an interview.
“One of the big things about being at the meeting is interacting with your colleagues from the different specialties to continue to work toward more integrated treatment of the vascular patient. The goal is working together for the patient’s greater good irrespective of your specialty,” Ansel, a member of the steering committee for the meeting, told Cardiology Today’s Intervention. “Also, the meeting enables us to continue to see that the field is maturing. We’re getting long-term results for trials. It used to be that we did not have great data sets to tell you what you should be doing. But we’re starting to get to where we’re seeing potential algorithms for patients with different vascular disease processes.”
The meeting will feature 20 late-breaking clinical trials, including:
- 1-year results from the SENTRY trial of a bioconvertible inferior vena cava filter (Sentry IVC, Novate Medical) that does not need to be removed;
- two studies of a drug-coated balloon (In.Pact Admiral, Medtronic): 2-year results from the IN.PACT Global study of a real-world cohort and 4-year results of the IN.PACT SFA pivotal trial of the DCB vs. an uncoated balloon catheter in femoropopliteal lesions;
- primary patency results of the Mimics study of a 3-D helical stent (BioMimics, Veryan Medical) for treatment of patients with symptomatic peripheral artery disease;
- 2-year outcomes from the atherectomy cohort of the DANCE trial of a micro-infusion device (Bullfrog, Mercator Medsystems) for treatment of PAD;
- a subanalysis of DETOUR I, which assessed the safety and efficacy of a novel percutaneous bypass procedure for long-segment femoropopliteal lesions;
- results of the PREVEIL trial, a feasibility study of a novel DCB (SurVeil, SurModics); and
- two studies comparing results of endovascular aneurysm repair by sex: the ENGAGE registry and the LUCY prospective multicenter study.
- subgroup analyses from the ACT I trial of outcomes with carotid stents in women and in patients with atherosclerotic burden.
The event for the second year includes the Veins meeting, which “has been a great addition to VIVA,” Ansel said.
The meeting also includes sessions that focus on pharmacotherapy, critical limb ischemia, tibial intervention, abdominal aortic aneurysm repair, venous disease, wound care, pulmonary embolism management, neurovascular procedures and chronic total occlusions.
“Not only are we seeing new technology, but we’re seeing longer-term follow-up results, which as the field matures, are very important to us,” Ansel told Cardiology Today’s Intervention. “We’re getting a lot more focus on the best value care for patients that are being treated.” – by Erik Swain
Disclosures: Cardiology Today’s Intervention is an official media partner of VIVA 17. Ansel reports he serves on advisory boards for Abbott Vascular, Boston Scientific, Cook Medical, C.R. Bard, Medtronic, Novate Medical, Philips, Spectranetics, Variant and W.L. Gore and Associates.